Finding needles in haystacks: OMass unveils pipeline aimed at tough-to-drug targets

Published

November 17, 2021

Finding needles in haystacks: OMass unveils pipeline aimed at tough-to-drug targets

There’s not yet proof of the pudding, but OMass Therapeutics Ltd.’s new structure-based technology has passed a key test, in enabling the discovery of orally available small…

MORERelated News
Biotech Review of the Year
The main challenge in 2023 was that global economic conditions (war in Ukraine, war in the Middle East, increasing interest...
The Life Sciences Sector Successfully Toughs Out Economic Challenges
Miguel Silva, Strategy Director at OMass Therapeutics which spun out of the University of Oxford. The company uses novel biochemistry...
Scrip Asks…What Does 2024 Hold For Biopharma? Part 1: Business Strategy And Leadership
Ros Deegan, CEO at OMass Therapeutics, Ltd, which develops new treatments using novel mass spectrometry approaches, also urged boldness (as well...